(0.25%) 5 104.00 points
(0.58%) 38 605 points
(0.57%) 17 750 points
(0.33%) $79.21
(-0.93%) $2.02
(0.29%) $2 316.20
(0.51%) $26.97
(0.51%) $967.50
(-0.07%) $0.932
(-0.25%) $10.96
(-0.13%) $0.797
(0.69%) $91.76
Live Chart Being Loaded With Signals
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific...
Stats | |
---|---|
Šios dienos apimtis | 5 527.00 |
Vidutinė apimtis | 25 032.00 |
Rinkos kapitalizacija | 5.43B |
EPS | SEK0 ( 2024-04-24 ) |
Kita pelno data | ( SEK1.730 ) 2024-07-18 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | 38.49 |
ATR14 | SEK0.628 (0.28%) |
CellaVision AB (publ) Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
CellaVision AB (publ) Finansinės ataskaitos
Annual | 2023 |
Pajamos: | SEK677.29M |
Bruto pelnas: | SEK463.04M (68.37 %) |
EPS: | SEK5.46 |
FY | 2023 |
Pajamos: | SEK677.29M |
Bruto pelnas: | SEK463.04M (68.37 %) |
EPS: | SEK5.46 |
FY | 2022 |
Pajamos: | SEK639.34M |
Bruto pelnas: | SEK438.32M (68.56 %) |
EPS: | SEK4.96 |
FY | 2021 |
Pajamos: | SEK565.55M |
Bruto pelnas: | SEK392.30M (69.37 %) |
EPS: | SEK5.25 |
Financial Reports:
No articles found.
CellaVision AB (publ)
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.